Effectiveness of ketamine in depressed patients resistant to ECT or rTMS therapy.

Abstract

prof. dr hab. n. med. P. Bieńkowski Summary Objectives. In the last decade several authors described a robust and clinically relevant alleviation of depressive symptoms after infusions of the uncompetitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonist-ketamine. In the majority of published reports ketamine was administrated to patients with depression resistant to pharmacotherapy, but not to ECT. We present a series of 5 subjects suffering from multimodal treatment-resistant depression (including ECT or rTMS and various medications) treated with intravenous infusions of ketamine in a subanesthetic dose of 0.5 mg/kg in the naturalistic setting. To the best of our knowledge it is the first report on ketamine infusion in patient resistant to antidepressants and rTMS Methods. Two subjects have been diagnosed with MDD, one with BD, two with severe depressive episode. The efficacy and possible adverse events were monitored using psychometric scales. Basic life parameters and ECG were observed. Results. Ketamine's infusions showed transient antidepressant efficacy. Improvement rate in our group was significant lower than in previously reported. Ketamine was generally well tolerated. We noted transient BP variations and appearance of mild and transient dissociative symptoms. Low early response rate may be correlated with resistance to previous multimodal treatment, high rate of somatization and anxiety comorbidity or heterogeneity of our group. Conclusions. Our findings do not support the use of ketamine infusions as the monotherapy in the subgroup of patients with multimodal treatment resistant depression.

Efficacy and safety of ketamine for the treatment of depressive symptoms in palliative care: A systematic review

“…Among them, one was diagnosed with breast cancer. 47 This 51-year-old woman received a single 0.5 mg/kg IV ketamine infusion. Her Montgomery-Asberg Depression Rating Scale (MADRS) 48 score was 38 at 2 h before infusion, which dropped to 27 at 120 min after infusion but returned to 39 after 24 h upon treatment discontinuation.…”

The role of gut microbiota in the pathogenesis and treatment of postpartum depression

“…Glutamate (or glutamine) is another disturbed AAs and their levels are significantly elevated in the brain, cerebrospinal fluid, and plasma of patients with depression [ 105 ]. Glutamate is an agonist of the N -methyl- d -aspartate (NMDA) receptor, and interestingly, NMDA receptor antagonists such as ketamine have been reported to show rapid antidepressant properties in animal models of depression as well as in depressed patients, by inhibiting glutamatergic neurotransmission [ 106 ].…”

Ketamine used in the therapy of depressive disorders impacts protein profile, proliferation rate, and phagocytosis resistance of enterococci

“…At first, it was used as an anesthetic and analgesic agent, but following that, its ability to block NMDA (glutamate N-methyl-D-aspartate calcium channels) receptors was discovered and the usage of the drug in psychiatry was also approved [1]. The approval of ketamine as a drug came first for hyperalgesia [2] and then for schizophrenia [3], but later on it was also used for treatment of resistant unipolar and bipolar depressions [4,5,6]. Its rapid action, its effectiveness in combating the symptoms, and its benign and transient adverse effects back up its common, current usage [7].…”